ZyVersa Therapeutics
ZVSA
ZVSA was delisted on the 16th of July, 2025.
24 hedge funds and large institutions have $62.2M invested in ZyVersa Therapeutics in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
14% more funds holding
Funds holding: 21 → 24 (+3)
12% more capital invested
Capital invested by funds: $55.4M → $62.2M (+$6.75M)
0.02% more ownership
Funds ownership: 0.2% → 0.22% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$2.79M |
| 2 |
D.E. Shaw & Co
New York
|
+$2.32M |
| 3 |
Barclays
London,
United Kingdom
|
+$1.38M |
| 4 |
SCM
Saba Capital Management
New York
|
+$1.09M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$521K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MSU
Mizuho Securities USA
New York
|
-$1.83M |
| 2 |
FLC
Fifth Lane Capital
Austin,
Texas
|
-$496K |
| 3 |
CCM
Context Capital Management
Lajolla,
California
|
-$62.6K |
| 4 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$20.9K |
| 5 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$6.95K |
ZVSA Hedge Fund Activity: Q2 2022 in Review
24 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q2 2022, worth a combined $62.2M — up 12% from $55.4M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ZVSA positions and 3 closed out — a net gain of 3 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Periscope Capital, adding an estimated $2.79M. The largest seller was Mizuho Securities USA, exiting entirely with an estimated $1.83M sold.
- 24 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q2 2022, up from 21 in Q1 2022.
- Funds reported $62.2M of ZyVersa Therapeutics stock for Q2 2022, up 12% quarter-over-quarter.
- 6 funds opened new ZyVersa Therapeutics positions in Q2 2022 and 3 closed out, a net change of +3 holders.
- The largest ZyVersa Therapeutics buyer in Q2 2022 was Periscope Capital, an estimated $2.79M added.
- The largest ZyVersa Therapeutics seller in Q2 2022 was Mizuho Securities USA, an estimated $1.83M sold.
Based on aggregated 13F filings for Q2 2022.